Last reviewed 2026-04-20 · How we verify

Axid Ar (NIZATIDINE)

Nizatidine (Axid AR) is a marketed H2 receptor antagonist primarily indicated for the treatment of active duodenal ulcers, competing in a mature market with off-patent generics such as cimetidine, ranitidine, and famotidine. Its key strength lies in its mechanism of action, which effectively blocks histamine receptors to reduce acid production and promote ulcer healing. The primary risk is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

• Active Duodenal Ulcer Treatment
• Maintenance Therapy for Duodenal Ulcer
• Esophagitis Treatment
• Active Benign Gastric Ulcer Treatment

Common side effects

• Headache
• Abdominal pain
• Pain
• Asthenia
• Back pain
• Chest pain
• Infection
• Fever
• Surgical procedure
• Injury, accident
• Diarrhea
• Nausea

Drug interactions

• dasatinib
• erlotinib

Key clinical trials

• Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19
• Clinical Trial to Compare Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis (PHASE4)
• [KJ-INT-002] BE Study (PHASE1)
• Improvement of Tinnitus After Oral Zinc on Patients With Noise-induced Hearing Loss (NA)
• Prophylaxis for Aspiration of Gastric Contents. (PHASE4)
• Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
• Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects (PHASE1)
• Drug-Drug Interaction Study With Metformin and Nizatidine (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.